A snake venom phospholipase A(2) blocks malaria parasite development in the mosquito midgut by inhibiting ookinete association with the midgut surface.
Oocyst formation is a critical stage in the development of the malaria parasite in the mosquito. We have discovered that the phospholipase A(2) (PLA2) from the venom of the eastern diamondback rattlesnake (Crotalus adamanteus) inhibits oocyst formation when added to infected chicken blood and fed to mosquitoes. A similar transmission-blocking activity was demonstrated for PLA2s from the venom of other snakes and from the honeybee. This effect is seen both with the avian malaria parasite Plasmodium gallinaceum and with the human parasite Plasmodium falciparum developing in their respective mosquito hosts. The inhibition occurs even in the presence of an irreversible inhibitor of the active site of PLA2, indicating that the hydrolytic activity of the enzyme is not required for the antiparasitic effect. Inhibition is also seen when the enzyme is fed to mosquitoes together with ookinetes, suggesting that the inhibition occurs after ookinete maturation. PLA2 has no direct effect on the parasite. However, pretreatment of midguts with PLA2 (catalytically active or inactive) dramatically lowers the level of ookinete/midgut association in vitro. It appears, therefore, that PLA2 is acting by associating with the midgut surface and preventing ookinete attachment to this surface. Thus, PLA2 is an excellent candidate for expression in transgenic mosquitoes as a means of inhibiting the transmission of malaria.
Zieler
H
H
Medical Entomology Section, Malaria Vaccines Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-0425, USA. zieler@chromatininc.com
Keister
D B
DB
Dvorak
J A
JA
Ribeiro
J M
JM
D000330:Aedes / Q000469:parasitology; D000818:Animals; D000852:Anopheles / Q000469:parasitology; D003435:Crotalid Venoms / Q000201:enzymology*; D017839:Crotalus; D009033:Culicidae / Q000469:parasitology*; D010741:Phospholipases A / Q000494:pharmacology*; D054467:Phospholipases A2; D010961:Plasmodium / Q000187:drug effects / Q000254:growth & development*; D010963:Plasmodium falciparum / Q000187:drug effects / Q000254:growth & development; D010964:Plasmodium gallinaceum / Q000187:drug effects / Q000254:growth & development
D003435:Crotalid Venoms; D010741:Phospholipases A; D054467:Phospholipases A2